Current role and future perspectives of hyperthermia for prostate cancer treatment

In Vivo

Volumn 23, Issue 1, 2009, Pages 143-146

  Baronzio, Gianfranco ^a   Gramaglia, Alberto ^a   Fiorentini, Gianmaria ^b  

^a Policlinico di Monza   (Italy)

^b SAN GIUSEPPE HOSPITAL   (Italy)

Author keywords

Conformal radiotherapy; Evidence based medicine; Hyperthemia; Prostate cancer; Review; Salvage therapy

Indexed keywords

ADVANCED CANCER; ANDROGEN ABLATION THERAPY; CANCER HORMONE THERAPY; CANCER THERAPY; COMPUTER ASSISTED RADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; HIGH INTENSITY FOCUSED ULTRASOUND; HORMONE RESISTANCE; HUMAN; HYPERTHERMIC THERAPY; INTERMETHOD COMPARISON; LOCOREGIONAL HYPERTHERMIA; MICROWAVE THERAPY; NONHUMAN; PROSTATE CANCER; RADIOFREQUENCY ABLATION; RADIOISOTOPE THERAPY; REVIEW; ADENOCARCINOMA; MALE; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; HUMANS; HYPERTHERMIA, INDUCED; MALE; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 63049133937     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Fleshner N and Zlotta AR: Prostate cancer prevention: past, present, and future. Cancer 110: 1889-1899, 2007.
2. Sugar LM: Inflammation and prostate cancer. Can J Urol 13(Suppl 1): 46-47, 2006.
3. Dahm P, Kunz R and Schünemann H: Evidence-based clinical practice guidelines for prostate cancer: the need for a unified approach. Curr Opin Urol 17: 200-207, 2007.
4. Gillett MD, Gettman MT, Zincke H et al: Tissue ablation technologies for localized prostate cancer. Mayo Clin Proc 79: 1547-1555, 2004.
5. Marberger M: Energy-based ablative therapy of prostate cancer: high-intensity focused ultrasound and cryoablation. Curr Opin Urol 17: 194-199, 2007.
6. Villa S: Hyperthermia and radiotherapy in the management of prostate cancer. In: Hyperthermia in Cancer Treatment. A Primer. Baronzio GF and Hager ED (eds.). Georgetown, Landes-Springer Publishers pp. 183-189, 2006.
7. Tucker RD, Platz CE, Huidobro C et al: Interstitial thermal therapy in patients with localized prostate cancer: histologic analysis. Urology 60: 166-169, 2002.
8. Baronzio GF, De Simone M, Fiorentini GM et al: Future perspectives of interstitial and perfusional hyperthermia. In: Hyperthermia in Cancer Treatment. A Primer. GF Baronzio and Hager ED (ed.). Georgetown, Landes-Springer Publishers pp. 338-360, 2006.
9. Burr JM, Hay DJ, Ludgate S et al: Hot and cold technologies for tissue ablation in urology. BJU Int 98: 1149-1153, 2006.
10. Small EJ and Vogelzang NJ: Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 15: 382-388, 1997.
11. Sharif N, Gulley JL and Dahut Wl: Androgen deprivation therapy for prostate cancer. JAMA 294: 238-244, 2005.
12. Pollack A, Zagars GK and Kopplin S: Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int J Radiat Oncol Biol Phys 32: 13-20, 1995.
13. American Society for Therapeutic Radiology and Oncology Consensus Panel: PSA relapse definitions - the Vancouver Rules show superior predictive power. Int J Radiat Oncol Biol Phys 43: 699-700, 1999.
14. Bruns F, Franzki C, Wegener G et al: Definitive conformal radiotherapy for localized high-risk prostate cancer: a long-term follow-up study with PSA course. Anticancer Res 27: 1847-1852, 2007.
15. Kupelian PA, Potters L, Khuntia D et al: Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage TI- T2 prostate cancer. Intl Radiat Oncol Biol Phys 58: 25-33, 2004.
16. Maluta S, Dall'Oglio S, Romano M et al: ConformaI radiotherapy plus hyperthermia in patients affected by locally advanced high-risk prostate cancer: preliminary results of a prospective phase Il study. Int J Hyperthermia 23: 451-456, 2003.
17. Van Vulpen M, De Leeuw IR1, Van Gellerkom MPR et al: A prospective quality of life study in patients with locally advanced pro state cancer, treated with radiotherapy with or without regional or interstitial hyperthermia. Int J Hyperthermia 19: 402-413, 2003.
18. Tilly W, Gellermann 1, Graf R et al: Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced pro state cancer T3 pNo Mo. Strahlenther Onkol 205: 35-41, 2005.
19. Algan O, Fosmire H, Hynynen K et al: External beam radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate carcinoma. Cancer 89: 399-403, 2000.
20. Pajonk F, van Ophoven A and McBride WH: Hyperthermia induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells. Cancer Res 65: 4836-43, 2005.
21. Isaacs JT and Isaacs WB: Androgen receptor outwits prostate cancer drugs. Nat Med 1: 26-27, 2004.
22. Tsukada T, Inoue M, Tachibana S et al: An androgen mutation causing androgen resistance in undervirilized male syndrome. 1 Clin Endocrinol Metab 79: 1202-1207, 1994.
23. Kalapurakal A, Mittal BB and Sathiaseelan V: Re-irradiation and external hyperthermia in locally advanced, radiation recurrent, hormone refractory prostate cancer: a preliminary report. Br J RadioI 4: 745-751, 2001.
24. Kalapurakal A, Pierce M, Chen A and Sathiaseelan V: Efficacy of irradiation and external hyperthermia in locally advanced, hormone-refractory or radiation recurrent prostate cancer: a preliminary report. Int J Radiat Oncol Biol Phys 57: 654-664, 2003.
25. Mohamed F, Marchettini P, Stuart A et al: Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 10: 463-468, 2003.
26. Nagel ID, Kruger I, Ghussen F et al: Clinical pharmacokinetics of mitoxantrone in hypertherniic, isolated perfusion of leg. Cancer Chemother Pharmacol 29: 155-158, 1991.